Ashwagandha's muscle-building case rests on three small, fragile trials

Ashwagandha has moved from traditional herb to mainstream gym supplement, and it is increasingly sold on the promise that it amplifies the strength and muscle-size gains produced by lifting. Previous attempts to pool the evidence mixed together trials from very different exercise contexts, which makes it hard to say whether the herb does anything for people following a structured resistance-training programme specifically. This review set out to answer that narrower and more useful question: when ashwagandha is added to proper lifting, does it improve strength, chest circumference or body composition? For a supplement with this much marketing behind it, that is exactly the test worth running.

The reviewers searched twelve bibliographic sources, including PubMed and Cochrane CENTRAL, plus two trial registers, with no date restriction up to 23 August 2026. They looked for randomised controlled trials combining a standardised ashwagandha extract, from root or root and leaf, with structured resistance training in healthy adults. Screening, data extraction and risk-of-bias assessment were carried out independently in duplicate. Four trials qualified; three of them, covering 161 participants, provided data that could be pooled, while one preprint was described narratively because its bench-press values could not be read as absolute loads. Changes from baseline were pooled with random-effects models, backed by several sensitivity analyses and a formal grading of how certain the evidence is.

Ashwagandha was associated with greater gains than placebo in one-rep-max bench press (standardised mean difference 0.60), lower-body one-rep max (0.52) and chest circumference (0.86), but there was no significant effect on body fat. Disagreement between trials was low to moderate, yet all three pooled trials raised at least some quality concerns. Under a stricter statistical adjustment, both strength effects lost significance, and each depended on a single influential trial. For chest circumference only two trials contributed, and the adjusted result was too imprecise to be informative. Certainty was rated low for both strength outcomes and body fat, and very low for chest circumference.

This review reframes rather than overturns earlier work. Previous pooled analyses that blended different exercise contexts had suggested benefits; confining the question to structured resistance training still leaves a signal for maximal strength and, indirectly, upper-body girth, but one that is statistically fragile and built on a very small evidence base. The authors conclude that current evidence does not establish a meaningful boost to resistance-training adaptations, and they call for adequately powered, independently funded trials using direct measures of muscle growth. It is also worth noting that the review itself received no external funding and was not registered, and that none of the pooled outcomes achieved better than low certainty.

If you lift and have seen ashwagandha promoted as a strength and size amplifier, this is a reason to hold that claim loosely. The most generous reading of the current evidence is a possible, unproven benefit to maximal strength, driven by a small number of imperfect trials, any one of which could tip the overall result. There is no dependable evidence here that it reduces body fat. None of that rules the herb out for other purposes, but on muscle and strength specifically, the training itself remains the part of the equation with solid evidence behind it.